The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leukoencephalopathy (PML). To correlate natalizumab-induced phenotypic modifications of peripheral blood T-lymphocytes with JCV reactivation, JCVspecific antibodies (serum), JCV-DNA (blood and urine), CD49d expression and relative abundance of peripheral blood T-lymphocyte subsets were longitudinally assessed in 26 natalizumab-treated RRMS patients. Statistical analyses were performed using GraphPad Prism and R. Natalizumab treatment reduced CD49d expression on memory and effector subsets of peripheral blood T-lymphocytes. Moreover, accumulation of peripheral blood CD8 + memory and effector cells was observed after 12 and 24 months of treatment. CD4 + and CD8 + T-lymphocyte immune-activation was increased after 24 months of treatment.
Introduction
CD49d is an α 4 -integrin that associates with β 1 -integrin to form the very late antigen-4 (VLA-4) or with β 7 -integrin to form the lymphocyte Peyer's patch adhesion molecule (LPAM). VLA-4 controls the migration of mononuclear leukocytes into the central nervous system (CNS) [1] [2] [3] [4] [5] . Blockade of CD49d with the humanized monoclonal antibody natalizumab suppresses trafficking of inflammatory leukocytes into the CNS [3] and leads to a significant decrease in the clinical relapse rate of the relapsing-remitting form of multiple sclerosis (RRMS) [6] . Natalizumab is currently the most effective therapy against RRMS [7] , however, its therapeutic efficacy is clouded by reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leukoencephalopathy (PML) [8] .
JCV infects a large portion of individuals worldwide [9, 10] and establishes lifelong persistent infection in kidneys, tonsils, bone marrow and CNS [11] [12] [13] [14] [15] [16] . The Stratify JCV1 assay is a validated test to measure anti-JCV antibodies in human serum and is currently used to stratify MS patients for higher or lower risk of developing PML [17] . However, due to the occurrence of JCV infection without the development of detectable antibody responses, additional markers are required in order to appropriately stratify patients.
Previous work has shown that natalizumab treatment increases the pool of circulating activated T-cells and other lymphocytes and decreased CD49d surface expression [18] . Therefore, the aim of this study was to longitudinally assess CD49d expression and CD4
+ and CD8 + Tlymphocyte phenotype alterations in the peripheral blood of natalizumab treated RRMS patients, in relationship with JCV reactivation.
Materials and Methods

Study population
26 subjects diagnosed with RRMS were enrolled at the Department of Neurology and Psychiatry of the University of Rome "Sapienza" between March 2012 and March 2014. Samples were collected before the first natalizumab infusion (T0), 12 and 24 months post-treatment initiation (T1 and T2, respectively). The therapeutic protocol consisted of administration of 300 mg intravenous natalizumab every 4 weeks. A "washout" period of at least 1 month for immunomodulatory drugs and 6 months for immunosuppressive drugs was mandatory before the initial natalizumab administration. All patients regularly underwent a complete physical and neurological examination and neurological disability was assessed by the Expanded Disability Status Scale (EDSS) score. Sixteen healthy donors (HD), age and sex matched with the RRMS patients, were enrolled as a control group. This study was approved by the Ethics Committee of Policlinico Umberto I of Rome (protocol number 130/13). All study participants fulfilled the Italian Agency of Drug (AIFA) criteria for natalizumab (Tysabri1) treatment and provided a written informed consent. and stored at -80°C until use. Heparin whole blood was used for multi-color flow cytometry immunophenotyping.
Detection of JCV antibodies
The presence of JCV specific antibodies in the serum of patients at baseline (n = 16), 12 and 24 months post-natalizumab treatment (n = 26) was assessed using the Stratify JCV 1 assay, which is a two-step enzyme-linked immunosorbent assay, able to detect anti-JCV specific IgG, with a sensitivity of 350 ng/ml.
Detection of viral genome by qPCR
DNA was extracted from 1x10 6 PBMCs, 200μL of EDTA plasma or urine, using the DNeasy1
Blood & Tissue Kit (QIAGEN, S.p.A, Milan, Italy), according to the manufacturer's instructions. DNA yield was determined by measuring the absorbance at 260nm in the eluate. The JCV T-antigen gene was detected and quantified in duplicate in extracted DNA by Real-Time PCR (Q-PCR) using a 7300 Real-Time PCR System (Applied Biosystems, USA), as previously described [19] . Nested PCR was employed for JCV hyper variable non-coding control region (NCCR) analysis, as previously reported [19] . The PCR product was purified with the QIAquick PCR purification kit (QIAGEN, S.p.A., Milan, Italy), and DNA sequencing was performed using an automatic DNA sequencer (Applied Biosystems, model 370 A), according to the manufacturer 0 s specifications. Sequences were organized and analyzed using the Genetic Computer
Group Sequence Analysis software package [19] .
Flow cytometry analysis of CD4 + and CD8 + T-lymphocytes
Immune activation, senescence and maturation subsets of peripheral blood T-lymphocytes were evaluated by flow cytometry using heparin whole blood direct staining. Briefly, 50μl of heparinized blood was incubated with fluorochrome-conjugated monoclonal antibodies for 30 minutes at 4°C in the dark. After red blood cells lysis, cells were washed and analyzed on a MACS Quant flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). The antihuman monoclonal antibodies used were: PacificBlue-CD3 (clone HIT3a), APC/Cy7-CD4 (clone RPA-T4), PE/Cy7-CD8 (clone SK1), FITC-CD28 (clone CD28.2), APC-CD38 (clone HIT2), PacificBlue-CD45 (clone HI30), PE-CD45RO (clone UCHL1), PE-CD57 (clone HCD57) and PerCp/Cy5.5-HLA-DR (clone L243) from Biolegend (Franklin Lakes, New Jersey, USA); PerCp-CD3 (clone SK7), FITC-CD27 (clone M-T271), APC-CD49d (clone 9F10) and APC Mouse IgG1-isotype Control from BD Biosciences (San Jose, California, USA). The antiCD49d antibody used in these experiments was not impacted by natalizumab binding [20] . CD4 and CD8 Maturation subsets were defined according to CD45RO 
Results
Description of MS patients
Twenty-six patients (15 females, 11 males) with clinically definite RRMS were included in the study. Sixteen patients were followed for all three time points (T0, T1 and T2), while ten patients were included at T1 and T2. Sixteen HD, age and sex matched with the 16 patients followed from T0, were enrolled as a control group Clinical and demographic characteristics are shown in Table 1 .
Stratify JCV
1
The presence of anti-JCV antibodies was evaluated through the qualitative Stratify JCV 1 test. b) Therapy before starting natalizumab.
c) Stratify JCV 1 : 2-step virus-like particle-based enzyme-linked immunosorbed assay (ELISA) was performed at T0, T1 and T2, to detect specific anti-JC virus antibodies in serum of the enrolled subjects.
defined as JCV+ when JCV-DNA was detected either in (1) blood, (2) urine or (3) blood and/ or urine. Subjects without detectable JCV-DNA in these analyses were defined as JCV-. A nonsignificant increase of JCV-DNA positivity was found from T0 to T2 in 16 patients (Fig 2A) and from T1 to T2 in all 26 patients (Fig 2B) in either blood, urine or blood and/or urine. No statistical differences between JCV-DNA viral load in blood or urine were detected at any time point (Fig 3) . JCV-NCCR sequencing revealed an archetypal organization of this region in all samples. When comparing JCV-DNA and anti-JCV antibody detection as methods for identifying JCV-infected individuals, we found that 3/16 JCV+ subjects (2 in blood and 1 in both ; SE = ±11.6), respectively. Differences were not statistically significant (urine: p = 0.72, blood: p = 0.90; statistical analysis performed using the 2-tailed χ 2 test). Combining blood and urine results (positivity corresponds to JCV-DNA detectability in at least one of the two samples), the percentage of positivity was 37.5% (6/16; SE = ±12.1), 31.2% (5/16; SE = ±11.6) and 37.5% (6/16; SE = ±12.1) at T0, T1 and T2, respectively, with no statistically significant differences (p = 0.91; statistical analysis performed using the 2-tailed χ 2 test). Whiskers represent standard errors. (B) Among all 26 RRMS patients, the percentage of positivity for JCV-DNA at T1 and T2, for urine was 23.1% (6/26; SE = ±8.2) and 26.9% (7/26; SE = ±8.7), and for blood was 19.2% (5/26; SE = ±7.7) and 34.6% (9/26; SE = ±9.3), respectively. Differences were not statistically significant (urine: p = 1.0, p = 0.35; statistical analysis was performed using the 2-tailed Ficher's exact test). Combining blood and urine JCV-DNA results, the positivity rate was 26.9% (7/26; SE = ±8.7) and 38.5% (10/26; SE = ±9.5) at T1 and T2, respectively, with no statistically significant differences (p = 0.56; statistical analysis was performed using the 2-tailed Ficher's exact test). Whiskers represent standard errors. (C) In the RRMS patients followed at T0 (n = 16), T1 and T2 (n = 26), the discordance between the PCR for JCV-DNA detection in blood and urine and the Stratify JCV1 test was 18,8% (3/16), 11,5% (3/26) and 19,2% (5/26) of cases at T0, T1 and T2, respectively. Stratify+: subjects positive for the Stratify JCV1 test. JCV+: subjects with JCV-DNA detection in blood and/or urine. JCV+ Stratify-: subjects positive for JCV-DNA detection in blood and/or urine, and negative for the Stratify JCV1 test. RRMS: relapsing-remitting form of multiple sclerosis.
doi:10.1371/journal.pone.0160277.g002 , and T2 (9/26). Symbols in gray represent subjects with JCV-DNA positivity only in PBMC, while plasma resulted negative. No statistical differences were found (one-way ANOVA test for non-parametrical data, Kruskal-Wallis). Results were expressed as log 10 gEq/ml for plasma, and log 10 gEq/10 6 cells for PBMC. Data are shown as median (lines) and interquartile ranges (whiskers). (B) Urine viral load of the RRMS patients who resulted positive for JCV-DNA detection at T0 (3/16), T1 (6/26), and T2 (7/26) . No statistical differences were found (one-way ANOVA test for non-parametrical data, Kruskal-Wallis). Results were expressed as log 10 gEq/ml. Data are shown as median (lines) and interquartile ranges (whiskers).
doi:10.1371/journal.pone.0160277.g003 blood and urine) at T0, 3/26 JCV+ subjects (1 in blood and 2 in urine) at T1 and 5/26 JCV+ subjects (3 in blood, 2 in both blood and urine) at T2 were negative for JCV serology according to the Stratify JCV1 assay (Fig 2C) .
Immunological results
CD49d expression analysis in peripheral blood T-lymphocytes from all 26 patients revealed statistically higher levels of median fluorescence intensity (MFI) on CD8 + compared to CD4 + at baseline, whereas no differences at T1 and T2 were observed (Fig 4A) . 
Relationship between immunological and virological data
To merge immunological and virological data, patients were divided into two groups according to JCV-DNA presence (JCV+) or absence (JCV-) in blood (plasma and or PBMCs) and/or urine samples. A statistically significant increase of total peripheral blood CD8 + T-lymphocyte percentages was observed in the JCV+ group compared to JCV-group at T1 and T2 ( Fig 6A  and 6B ); no differences were observed for total CD4 + T-lymphocyte frequencies at each followup time point. However, peripheral blood CD4 + E and CD8 + E percentages were higher in the JCV+ than JCV-group, at T2 while only CD8 + E were augmented in JCV+ subjects, at T1 (Fig   6C-6F) . Finally, significantly higher levels of CD4 immune activation were only found at T2 in JCV+ compared to JCV-subjects (CD4 (Fig 6G and 6H ).
Discussion
Although natalizumab is a highly effective drug for RRMS, potential life-threatening side effects, such as PML, are still a major challenge for affected individuals. To date, PML risk assessment and monitoring is based on clinical data, MRI scanning and JCV-specific antibody detection. Indeed, the routine monitoring of JCV serostatus using the Stratify JCV1 is now standard of care for RRMS patients [16] . However, due to high JCV seroprevalence both in the general population (60%) and MS patients (51%), the rare occurrence of PML (3.72 per 1000 natalizumab MS patients) makes this tool insufficient in defining the disease development risk [22, 23] underlining the need for appropriate biomarkers to better predict PML development. The validity of JCV-DNA detection in urine and blood samples as an early marker of PML development is still debated [24] [25] [26] [27] . The longitudinal monitoring of JCV-DNA in our cohort showed the occurrence of JCV viruria and transient viremia and the substantial stability of JCV-DNA detection rate after 12 and 24 months of natalizumab treatment, in agreement with previous studies [26, 27] . Interestingly, some patients who were Stratify JCV 1 negative, had detectable JCV-DNA viruria and/or viremia (Fig 2) . Despite an active replication of JCV, these patients are considered at low risk of developing PML, according to the negative result of the Stratify JCV 1 test. These data indicate that the Stratify JCV1 assay may not be as robust as other methods for identifying infected individuals. Furthermore, JCV serostatus alone does not allow for adequate screening of subjects harboring JCV and may therefore be at risk of PML when treated with natalizumab. Although we cannot state that JCV-DNA viruria and/or viremia itself is an early marker of PML, as none of the patients enrolled in this study developed PML, urine and/or blood JCV-DNA detection could be regarded as evidence of JCV presence in latency sites with potential spread to the CNS [28] . Besides JCV-DNA qPCR, NCCR sequencing could help in assessing PML development risk [19] . Recently, deep sequencing techniques of JCV-NCCR in blood and cerebrospinal fluid revealed a close relationship between the quasi-species harbored in these two body compartments [28] . As a consequence, testing for NCCR sequence in blood, an easily accessible body fluid, could provide hints about the viral presence in the CNS [29] . NCCR sequencing performed in all JCV-DNA positive urine and blood samples of our cohort revealed an archetypelike arrangement, which classically is not associated with PML development. This evidence could explain why PML development in these individuals was not observed.
It is known that the rearrangement of JCV-NCCR is necessary for PML development and possibly occurs in a replication-driven sequential series of events [30] . Under this assumption, natalizumab treatment and JCV replication could affect the host immune system, producing changes easily detected using peripheral blood flow cytometric analysis, thus providing viable biomarkers to identify patients at risk for PML development. CD49d monitoring on PBMCs has previously been proposed as a biological marker of natalizumab treatment efficacy being able to identify non-responding patients due to the development of neutralizing antibodies [20] .
Several studies have emphasized the role of CD49d in adhesion mechanisms of blood leukocytes to the extracellular matrix and migration from the bloodstream towards tissues and inflammation sites [2] [3] [4] [5] [6] . Furthermore, it has been shown that CD49d is a co-stimulatory molecule involved in T-lymphocyte activation, enhancing proliferation in response to OKT3 (an anti-CD3 monoclonal antibody) [31] . Our results demonstrated significantly higher levels of CD49d expression in CD8 + compared to CD4 + T-lymphocytes at baseline both in RRMS patients and HD; this significant difference was not seen after 12 and 24 months of natalizumab treatment in RRMS patients. Furthermore, we found that in natalizumab untreated MS subjects, CD49d was up-regulated in both CD4 + and CD8 + T-lymphocytes naïve cells once a memory or effector phenotype was acquired. In particular, for CD8 + T-lymphocytes, CD49d
was up-regulated in the early stage of differentiation, as demonstrated by the MFI increment in CD8 + I subset (Fig 4) . The same findings were observed in HD, indicating that CD49d expression pattern follows the same rules in T-lymphocytes of both untreated RRMS patients and HD. Natalizumab therapy progressively reduced CD49d expression in CD4 + and CD8 + CM, EM, E and CD8 + I cells (Fig 5) , leading to the accumulation of CD8 + and CD4 + T-lymphocytes in peripheral blood. Interestingly, CD8 + CM, EM and E exhibited the highest increases. Considering that the increment of these subsets in peripheral blood could correspond to a specular decrease in the CNS, these data indicate that the immune surveillance mechanisms of this compartment could be impaired in natalizumab-treated individuals [31] . The observed higher percentage of CD4 + and CD8 + HLA-DR + CD38 + at T2 confirmed the increased activation of T lymphocyte induced by natalizumab treatment. Moreover increased levels of immune activated CD4 + HLA-DR + CD38 + were found in JCV+ subjects, suggesting a direct role of the polyomavirus replication. Taken together, our data suggest that monitoring of CD49d expression could provide useful information to understand JCV reactivation mechanisms in natalizumab-treated RRMS patients. For that purpose, we directly compared our immunological and virological data and found that higher percentages of peripheral blood CD4 + and CD8 + E significantly associated with JCV-DNA viremia and/or viruria after 12 and 24 months of natalizumab treatment. Performing logistic regression and ROC analyses, peripheral blood CD8 + E percentage was predictive of JCV-DNA positivity (Fig 6) . The association between JCV reactivation and natalizumab treatment could be an indirect consequence of CD49d down-regulation. In fact, it has been reported that the number of circulating CD34 + hematopoietic stem cells are markedly increased in MS patients during natalizumab treatment [32] . It is not clear if this is a consequence of reduced CD34 + precursor adhesion or proliferation due to natalizumab binding to CD49d [33] . Bone marrow CD34 + hematopoietic precursors are considered one of the JCV latency sites and their increased circulation could spread the virus through the bloodstream into the CNS [34] . Therefore, the increased JCV circulation, together with the defective CNS immune surveillance, could explain JCV reactivation and PML development in natalizumab treated RRMS patients [35] . Our study has limitations. We did not explore natalizumab-induced modifications of Tlymphocyte phenotype in the CNS, because cerebrospinal fluid samples were not available from any of the patients. In addition, we did not evaluate the JCV-specificity of the memory and effector compartments of T-lymphocytes.
In conclusion, natalizumab treatment decreases CD49d expression on CD4 + and CD8 + Tlymphocyte memory and effector subsets over time, without affecting naïve cells. As a cansequence of CD49d decreased expression, we observed a progressive accumulation of CD8 memory and effector subsets in peripheral blood. Moreover, natalizumab significatively increased CD4 + and CD8 + T-lymphocyte immune activation after 24 months of treatment. In our study, increased peripheral blood CD8 + E percentages were associated with JCV-DNA positivity.
Taken together, these data indicate that natalizumab could mobilize and activate JCV infected cells from latency sites and reduce CD8 effector and memory subsets migration into CNS. JCV systemic spread from latency sites and impaired immune surveillance mechanisms in the CNS could explain the increased risk of PML development in natalizumab treated RRMS patients.
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